Leon Moulder, Jr. Purchases 60,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. purchased 60,000 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was bought at an average cost of $16.88 per share, for a total transaction of $1,012,800.00. Following the purchase, the chief executive officer directly owned 96,928 shares in the company, valued at $1,636,144.64. This represents a 162.48% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Zenas BioPharma Trading Down 7.8%

ZBIO traded down $1.43 during trading on Monday, reaching $16.91. The company had a trading volume of 1,163,015 shares, compared to its average volume of 497,699. The firm’s 50-day simple moving average is $21.04 and its 200 day simple moving average is $26.62. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -2.00 and a beta of -0.61. Zenas BioPharma, Inc. has a 12-month low of $8.91 and a 12-month high of $44.60. The company has a debt-to-equity ratio of 1.04, a quick ratio of 11.94 and a current ratio of 11.94.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. During the same period in the previous year, the firm posted ($0.80) earnings per share. Equities research analysts anticipate that Zenas BioPharma, Inc. will post -4.25 earnings per share for the current year.

Hedge Funds Weigh In On Zenas BioPharma

A number of hedge funds have recently added to or reduced their stakes in the company. SR One Capital Management LP increased its holdings in Zenas BioPharma by 2.6% in the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock worth $182,924,000 after buying an additional 126,315 shares during the last quarter. NEA Management Company LLC increased its holdings in Zenas BioPharma by 28.9% in the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock worth $127,928,000 after buying an additional 789,500 shares during the last quarter. Federated Hermes Inc. increased its holdings in Zenas BioPharma by 45.9% in the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock worth $98,603,000 after buying an additional 853,740 shares during the last quarter. Vanguard Group Inc. increased its holdings in Zenas BioPharma by 25.0% in the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after buying an additional 290,307 shares during the last quarter. Finally, Polar Capital Holdings Plc acquired a new position in Zenas BioPharma in the fourth quarter worth approximately $38,402,000.

Analyst Ratings Changes

ZBIO has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th. Guggenheim raised their price target on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Morgan Stanley raised their price target on shares of Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, HC Wainwright restated a “buy” rating and set a $44.00 price target on shares of Zenas BioPharma in a report on Friday. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Zenas BioPharma currently has a consensus rating of “Hold” and an average target price of $44.29.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.